This webinar provides a deeper understanding of the significance of morphological, immunohistochemical, and genomic information in shaping therapeutic decisions for managing mesothelioma.

• Part 1: Updated Pathology Considerations & Terminology in Mesothelioma
• Part 2: Immunohistochemical Staining for Separating Mesotheliomas from Other Tumors
• Part 3: The Separation of Benign from Malignant Mesothelial Proliferation

Presented by the IASLC Rare Tumors Committee

• Luka Brcic, MD, PhD, Medical University of Graz, Graz, Austria
• Andrew Churg, MD, PhD, Vancouver General Hospital, Vancouver, BC, Canada 
• Francoise Galateau-Salle, MD, MESOPATH College, Lyon, France

Upon completion of this activity, the participants should be able to:

• Recognize and summarize the types of mesothelioma and their variants with a focus on epithelioid mesothelioma.
• Define which epithelioid features have prognostic significance.
• Describe and explain the grading of mesothelioma and its prognostic role.
• Develop an appropriate immunohistochemical algorithm for the diagnosis of mesothelioma and its subtypes.
• Devise a management strategy for ‘’ in situ mesothelioma diagnosis’’.
• Identify In which patients molecular testing should be recommended to detect mutation.
• Underline the optimal samples required to include patients in clinical trials.

This activity is designed to meet the educational needs of healthcare professionals, pathologists, oncologists, researchers, and anyone seeking to deepen their knowledge in the rapidly evolving field of mesothelioma pathology.

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need any assistance with this activity, please email: education@iaslc.org.